--- title: "Summit files $380 million stock program as 10-Q flags going concern doubt" url: "https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-23" section: "Distress" tickers: "NASDAQ:SMMT" source: "https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm" summary: "Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM." --- By the aibio.space Summit desk. Sources - [Summit Therapeutics (SEC 424B5)](https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm) - [Summit Q2 2026 report](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) - [Summit 10-Q](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm) [SMMT](https://aibio.space/companies/summit-therapeutics/) 2026-07-23 # Summit files $380 million stock program as 10-Q flags going concern doubt Tickers [SMMT](https://aibio.space/companies/summit-therapeutics/) Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM. ## Key facts - **Company**: Summit Therapeutics Inc. (NASDAQ: SMMT) - **News type**: Distress - **Primary source**: [Summit Therapeutics (SEC 424B5)](https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm) *Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.* Summit Therapeutics filed a prospectus supplement on July 23 for an at-the-market stock program of up to $380 million, with J.P. Morgan Securities as sales agent. The [filing](https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm) says Summit sold the remaining $68.4 million under its earlier program after June 30. The same day, the company [reported](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) a second-quarter net loss of $215.7 million and cash and short-term investments of $690.7 million at June 30. ## The details Under the new [distribution agreement](https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm), Summit can sell common stock with an aggregate price of up to $380 million, and J.P. Morgan can take a commission of up to 3.0%. The prospectus used an illustrative sale of 25,780,189 shares at $14.74, the July 22 closing price. It listed 793,120,362 shares outstanding at June 30. The 10-Q cover page [gives](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm) 797,749,602 shares as of July 17. Summit said it will use the proceeds to continue developing ivonescimab, including trials in non-small cell lung cancer, colorectal cancer and other solid tumors, with the rest going to working capital and general purposes. The [second-quarter report](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) says Summit raised $230.8 million gross through its ATM facility in the quarter and another $68.4 million after June. Cash and short-term investments fell to $690.7 million from $713.4 million at Dec 31, 2025. Net cash used in operations for the six months was $263.4 million. GAAP net loss for the quarter was $215.7 million, or $0.28 a share, and non-GAAP net loss was $147.0 million. ## Context The [10-Q](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm) contains going concern language. It says cash and short-term investments are "not sufficient to fund the Company's planned operations for a period of at least one year" and that the conditions "raise substantial doubt about the Company's ability to continue as a going concern." Cash and equivalents were $419.4 million and short-term investments $271.3 million at June 30. The report gives no explicit runway guidance. Spending is rising because trials are. [Non-GAAP operating expenses](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) were $151.8 million in the second quarter, up from $89.6 million a year earlier, which the company ties to expansion of the ivonescimab program. The program includes HARMONi-3, HARMONi-7, a colorectal trial called HARMONi-GI3 and several combination studies. Summit also [sold](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026-2026.pdf) its antibiotic ridinilazole to Biossil in July for $500,000 upfront, up to $104.5 million in milestones and tiered royalties. ## What it means for investors The financing is a standard way for a company without product revenue to fund trials, and it dilutes existing holders each time it is used. Summit raised $230.8 million in a quarter in which its shares [fell sharply](https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble) after the HARMONi-3 interim result. A going concern note in a 10-Q is a formal accounting disclosure about the next twelve months, not a statement that cash will run out. It does mean that, as the [filing](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm) puts it, cash on hand did not cover a full year of planned operations without further financing, and the ATM is the company's answer. The size of the program, [$380 million](https://www.sec.gov/Archives/edgar/data/0001599298/000119312526314210/d39231d424b5.htm), is smaller than the roughly $690 million on hand, but it is large relative to quarterly operating spending. An FDA delay or a negative HARMONi-3 result would likely make further raises costlier. ## What to watch The FDA's goal date for the HARMONi application is [Nov 14, 2026](https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2026-2026.pdf). Third-quarter results should show how much of the $380 million program Summit has used. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SMMT Summit Therapeutics Inc. NASDAQ ยท United States Open the desk ## More from the Summit desk Legal ### [Summit Therapeutics derivative suit over $520 million Duggan notes ends in voluntary dismissal](https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/) Jul 23, 2026 Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 --- Source page: https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Summit files $380 million stock program as 10-Q flags going concern doubt", 2026-07-23, https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/